JDQ443 + TNO155 + tislelizumab
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS G12C Mutant Solid Tumors
Conditions
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Trial Timeline
Feb 24, 2021 → Jan 25, 2027
NCT ID
NCT04699188About JDQ443 + TNO155 + tislelizumab
JDQ443 + TNO155 + tislelizumab is a phase 1/2 stage product being developed by Novartis for KRAS G12C Mutant Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT04699188. Target conditions include KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04699188 | Phase 1/2 | Active |
Competing Products
20 competing products in KRAS G12C Mutant Solid Tumors